Compare BridgeBio Pharma Inc (BBIO) vs iShares MSCI Hong Kong ETF (EWH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs iShares MSCI Hong Kong ETF — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while iShares MSCI Hong Kong ETF trades at $21.82. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | EWH | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $90.17 | $24.55 |
52-Week Low | $44.81 | $20.09 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
EWH trades at $21.30, down 0.93% with a mixed technical outlook showing bullish overall signals but bearish moving averages. The stock faces resistance at $22 with support at $21. Recent news highlights Hong Kong's growing prominence as a wealth hub and market volatility in Asian indexes. Key financial ratios remain unavailable in current data.
The outlook remains cautious with technical resistance limiting near-term upside. Hong Kong's economic developments provide potential catalysts, but lack of fundamental data and mixed technical indicators suggest careful monitoring of earnings and market sentiment is essential for investment decisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →
